As of February 1, 2019, KyungDong Pharm Co., Ltd. launched the neuropathic pain treatment ‘Nucapen Capsule (pregabalin 75mg,

150mg)’ is released.

‘Nuccapen Capsule’ inhibits the influx of calcium into nerve terminals and reduces excessive secretion of excitatory neurotransmitters.

Reduces the pain of diabetic peripheral neuropathy and post-herpetic neuralgia, and is effective in treating patients with post-traumatic neuropathic pain.

Treatment satisfaction is high. Significantly improves sleep disorders caused by diabetic peripheral neuropathic pain

“Nucapen Capsule” is recommended as a Level A treatment for diabetic neuropathic pain.

Therefore, the launch of “Nucapen Capsule” by KyungDong Pharm Co., Ltd., which is effective for these indications, is effective in treating neuropathic pain.

It seems like it will be helpful.

 

♤ Product Information ♤

 

Product Name

Newcapen Capsule 75mg, 150mg

Ingredient content

1 tablet of Nucapen Capsule 75mg - Pregabalin 75mg

Nucapen Capsule 150mg - Pregabalin 150mg

Indications

1. Treatment of peripheral and central neuropathic pain in adults

2. Epilepsy - Adjuvant for partial seizures with or without secondary systemic symptoms in adults

3. Treatment of fibromyalgia

Dosage and usage

This drug is pregabalin, and the total daily dose is divided into two times a day and is administered orally regardless of food. Since this drug is mainly excreted by the kidneys, the dose should be adjusted for patients with reduced renal function.

 

1. Neuropathic pain

1) Peripheral neuropathic pain

Adults: The starting dose of this drug is 150 mg per day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose can be increased at subsequent 7-day intervals up to a maximum of 600 mg per day.

2) Central neuropathic pain

Adults: The starting dose of this drug is 150 mg per day. Based on the individual patient's response and tolerability, the dose can be increased to 300 mg per day after 1 week. After an additional week, the dose can be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered.

 

2. Epilepsy

Adults: The starting dose of this drug is 150 mg per day. Based on the individual patient's response and tolerability, the dose can be increased to 300 mg per day after one week. If necessary, the dose can be increased at 7-day intervals up to a maximum of 600 mg per day.

 

3. Fibromyalgia

The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The starting dose of this drug is 75 mg twice a day (150 mg per day), and based on effectiveness and tolerability, the dose can be increased by 150 mg twice a day (300 mg per day) within one week. For patients who do not experience sufficient benefit from the dose of 300 mg per day, the dose can be increased to 225 mg twice daily (450 mg per day) within one week. Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or sufficient tolerability at this dose. Considering dose-dependent adverse reactions, administration of doses exceeding 450 mg per day is not recommended.

 

Reimbursement Prices

Newcapen Capsule 75mg - 549 won/capsule, Newcapen Capsule 150mg - 700 won/capsule

Packaging unit

30 capsules/bottle

 

※ Please refer to the product manual for other details such as precautions for use.